Clinical trial • Cardiology

Bisoprolol fumarate, hydrochlorothiazide for Idiopathic ventricular fibrillation | Out-of-hospital cardiac arrest (unexplained cardiac arrest)

Clinical trial of Bisoprolol fumarate, hydrochlorothiazide for Idiopathic ventricular fibrillation | Out-of-hospital cardiac arrest (unexplained cardiac a…

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Idiopathic ventricular fibrillation | Out-of-hospital cardiac arrest (unexplained cardiac arrest)
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
30-09-2024
First CTIS Authorization Date
23-10-2024

Trial design

Randomised trial across 2 sites in Denmark.

Randomised
Yes
Target Sample Size
218
Trial Duration For Participant
1095

Eligibility

Recruits 218 adults.

Inclusion criteria

  • {"criterion_text":"- Unexplained cardiac arrest survivors aged 18 or older\n- All patients surviving a cardiac arrest will receive a minimum diagnostic work-up consisting of an ECG, a Holter monitor during admission, an echocardiography, consecutive blood samples during the first 24 hours, and a coronary angiography or a cardiac CT-scan. Further evaluation with SAECG, stress-ECG, Cardiac MRI, and Sodium-channel blocker testing will be performed subsequently\n- All patients will have an ICD implanted"}

Exclusion criteria

  • {"criterion_text":"- Age under 18 years\n- Explained cardiac arrest"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Endpoint will be one of the following 1) first appropriate therapy by ICD, 2) aborted shock or non-sustained VF, where the treating physician opts XML File Identifier: kg77bYwzweR7n2lb9bLtT2kXLeo= Page 25/34 for a change in medication, or 3) 3 years after randomizationdischarge, whichever comes first.","definition_or_measurement_approach":"Measured by ICD events (first appropriate therapy by ICD), aborted shock or non-sustained ventricular fibrillation leading to change in medication, or by time (3 years after randomization/discharge)."}

Secondary endpoints

  • {"endpoint_text":"- Quality of life after 1 year","definition_or_measurement_approach":"Not specified in the record."}

Recruitment

Planned Sample Size
218
Recruitment Window Months
115
Consent Approach
Not specified in the record; subject information and informed consent form documents are listed (L1_SIS and ICF documents present) but content/details (who provides consent, age-specific documents, languages) are not available in the provided JSON.

Geography

Total Number Of Sites
2
Total Number Of Participants
218

Denmark

Earliest CTIS Part Ii Submission Date
11-10-2024
Latest Decision Or Authorization Date
23-10-2024
Processing Time Days
12
Number Of Sites
2
Number Of Participants
218

Sites

Site Name
Rigshospitalet
Department Name
Cardiology
Principal Investigator Name
Bo Winkel
Principal Investigator Email
bo.winkel@regionh.dk
Contact Person Name
Bo Winkel
Contact Person Email
bo.winkel@regionh.dk
Site Name
Odense University Hospital
Department Name
Cardiology
Principal Investigator Name
Finn Henriksen
Principal Investigator Email
fhenriksen@health.sdu.dk
Contact Person Name
Finn Henriksen
Contact Person Email
fhenriksen@health.sdu.dk

Sponsor

Primary sponsor

Full Name
Rigshospitalet
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"Sponsor duties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"Denmark","full_name":"Odense University Hospital","duties_or_roles":"Sponsor duties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
BISOPROLOL
Active Substance
Bisoprolol fumarate, hydrochlorothiazide
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
oral
Maximum Dose
2.50 mg
Investigational Product Name
METOPROLOL
Active Substance
Metoprolol
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
oral
Maximum Dose
50 mg
Investigational Product Name
ATENOLOL
Active Substance
Atenolol, Chlortalidone
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
oral
Maximum Dose
25 mg
Investigational Product Name
NADOLOL
Active Substance
Nadolol
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
oral
Maximum Dose
40 mg
Investigational Product Name
PROPRANOLOL
Active Substance
Propranolol hydrochloride
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
oral
Maximum Dose
80 mg

Related trials

Other published trials that may interest you.